Progress in crafting marijuana plants that are high in the non-psychoactive marijuana cannabinoid cannabidiol (CBD) and tobacco that’s low in nicotine sent 22nd Century Group, Inc. (NYSEMKT:XXII) rocketing 157% higher in 2017, according to S&P Global Market Intelligence.

22nd Century is a plant biotechnology company that genetically engineers and breeds tobacco and cannabis plants to make them more valuable. Its primary work includes low-nicotine tobacco plants and hemp plants that can be used in soil remediation, but it’s also working on cannabis that’s high in CBD, a cannabinoid that’s been associated with positive outcomes in epilepsy patients.

Read More: 

Leave a Reply